Drug Profile

Ir CPI

Alternative Names: BIOX-101; Ir-CPI

Latest Information Update: 02 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Free University of Brussels
Developer Bioxodes
Class Antihaemorrhagics; Antithrombotics; Peptides
Mechanism of Action Factor XIa inhibitors; Factor XIIa inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Cerebral haemorrhage
New Molecular Entity No

Highest Development Phases

Phase II Cerebral haemorrhage

Most Recent Events

24 Apr 2025 Bioxodes plans to submit Ir CPI for conditional marketing authorisations for Cerebral haemorrhage in USA and Europe, before 2030
24 Apr 2025 Updated adverse events, efficacy, pharmacokinetics and pharmacodynamics data from the phase IIa BIRCH trial in Cerebral haemorrhage released by Bioxodes
24 Apr 2025 Bioxodes plans a phase II trial in acute ischemic Stroke

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com